Cargando…

Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges

Cancer is a top global public health concern. At present, molecular targeted therapy has emerged as one of the main therapies for cancer, with high efficacy and safety. The medical world continues to struggle with the development of efficient, extremely selective, and low-toxicity anticancer medicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Junxia, Chao, Tengfei, Liu, Yingying, Gong, Chen, Zhang, Yinan, Xiong, Huihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305175/
https://www.ncbi.nlm.nih.gov/pubmed/37376154
http://dx.doi.org/10.3390/pharmaceutics15061706
_version_ 1785065671496826880
author Liu, Junxia
Chao, Tengfei
Liu, Yingying
Gong, Chen
Zhang, Yinan
Xiong, Huihua
author_facet Liu, Junxia
Chao, Tengfei
Liu, Yingying
Gong, Chen
Zhang, Yinan
Xiong, Huihua
author_sort Liu, Junxia
collection PubMed
description Cancer is a top global public health concern. At present, molecular targeted therapy has emerged as one of the main therapies for cancer, with high efficacy and safety. The medical world continues to struggle with the development of efficient, extremely selective, and low-toxicity anticancer medications. Heterocyclic scaffolds based on the molecular structure of tumor therapeutic targets are widely used in anticancer drug design. In addition, a revolution in medicine has been brought on by the quick advancement of nanotechnology. Many nanomedicines have taken targeted cancer therapy to a new level. In this review, we highlight heterocyclic molecular-targeted drugs as well as heterocyclic-associated nanomedicines in cancer.
format Online
Article
Text
id pubmed-10305175
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103051752023-06-29 Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges Liu, Junxia Chao, Tengfei Liu, Yingying Gong, Chen Zhang, Yinan Xiong, Huihua Pharmaceutics Review Cancer is a top global public health concern. At present, molecular targeted therapy has emerged as one of the main therapies for cancer, with high efficacy and safety. The medical world continues to struggle with the development of efficient, extremely selective, and low-toxicity anticancer medications. Heterocyclic scaffolds based on the molecular structure of tumor therapeutic targets are widely used in anticancer drug design. In addition, a revolution in medicine has been brought on by the quick advancement of nanotechnology. Many nanomedicines have taken targeted cancer therapy to a new level. In this review, we highlight heterocyclic molecular-targeted drugs as well as heterocyclic-associated nanomedicines in cancer. MDPI 2023-06-10 /pmc/articles/PMC10305175/ /pubmed/37376154 http://dx.doi.org/10.3390/pharmaceutics15061706 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Liu, Junxia
Chao, Tengfei
Liu, Yingying
Gong, Chen
Zhang, Yinan
Xiong, Huihua
Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges
title Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges
title_full Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges
title_fullStr Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges
title_full_unstemmed Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges
title_short Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges
title_sort heterocyclic molecular targeted drugs and nanomedicines for cancer: recent advances and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305175/
https://www.ncbi.nlm.nih.gov/pubmed/37376154
http://dx.doi.org/10.3390/pharmaceutics15061706
work_keys_str_mv AT liujunxia heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges
AT chaotengfei heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges
AT liuyingying heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges
AT gongchen heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges
AT zhangyinan heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges
AT xionghuihua heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges